
Opinion|Videos|June 21, 2024
Clinical Pearls for the Management of Patients Suffering from Narcolepsy
Karl Doghramji, MD, FAASM, DFAPA, and Chelsie Monroe, MSN, APN, PMHNP-BC, conclude the discussion with advice for clinicians who treat patients with narcolepsy.
Advertisement
Episodes in this series

Advertisement
Related to this article

Bessel van der Kolk, MD, argues that trauma is rooted in attachment and that psychedelic-assisted therapy may help where medications have not.

Emestedastat did not significantly slow disease progression, but a prespecified analysis showed a higher rate of zero CDR-SB progression.

In this CME article, explore the clinical evidence and ethical reasoning to guide use of long-acting injectable antipsychotics in patient care.

In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.

2R,6R-HNK reproduces ketamine’s rapid antidepressant profile in rodents without dissociation or abuse signals, and is now in four phase 2 trials.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Why Depression Subtypes Matter: Lessons From 25 Years in the Clinic
2
Treatment of Repetitive Behaviors in Autism: Where Does the Evidence Stand?
3
DT-120 in Anxiety and Depression: Phase 3 Efficacy and Safety Findings
4
Podcast: Bessel van der Kolk, MD, on Trauma, Attachment, and the Limits of Pharmacotherapy for PTSD
5




